Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instruction can ...

Government College University Faisalabad (GCUF) has opened admissions for the Fall 2026-2027 session for undergraduate, ...

With a drug candidate in hand sooner than expected, NewLimit plans to push into a phase 1 fatty liver disease trial next year. (iStock / Getty Images Plus) Anti-aging startup NewLimit is back with a ...

Investors crowned Parabilis Medicines with the largest biotech initial public offering on record—then bid its shares up some 58% on their first day of trading Wednesday. Parabilis’s $670 million ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study No dose-limiting toxicities, serious adverse ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Above the scientific discussions and deal talks at ASCO 2026, the dark cloud of geopolitics hovered over the Chicago convention center. (Angus Liu/Fierce Pharma) In 2017, a little-known company called ...

The Fund seeks investment results that correspond generally to the price and yield of an equity index called the NYSE Arca Biotechnology Index. The Fund normally invests at least 90% of its net assets ...

After doing a BSc, there are many great career options available that give high salaries and better growth. Courses like MBA, MSc, Data Science, Biotechnology and Professional Certifications not only ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would give GSK two late ...